Biotech markets, read through the machinery.
BioCentury This Week treats biotech as both science and capital market. Its panel follows M&A, public financings, FDA movement, clinical data, and regional strategy with the assumption that listeners already know the sector’s vocabulary.
PRESS PLAY
BioCentury This Week is a sector-intelligence program for people who follow biotech as a business. It is less a general science show than a recurring editorial meeting about where capital, regulation, dealmaking, and therapeutic innovation are moving. The panel talks in specifics. Recent episodes have examined Biogen’s move into nephrology, Lilly’s bet on OX2R agonists, Gilead’s oncology reset, Arrowhead’s long platform arc, and Xenon’s late-stage epilepsy data. The show keeps returning to the same practical question: what changes a company’s trajectory? Sometimes the answer is a takeout. Sometimes it is a clinical inflection point, a financing window, a regulatory opening, or a policy shift that changes the risk calculation. FDA coverage is a major part of the mix, especially around complete response letters, CBER leadership, accelerated approval, orphan drug rules, and uncertainty in approval pathways. The market analysis is equally central. Public market previews, follow-on financings, IPO conditions, sentiment, and the durability of M&A all receive careful attention. The show also spends real time outside the U.S. Episodes from Seoul and Europe frame biotech competition through clinical-trial speed, capital formation, partnering, and ecosystem strategy. Europe’s challenge is discussed through pricing, trials, funding, and investor coalitions. Asia appears through the East-West Biopharma Summit, Korean biotech momentum, China policy, and cross-border partnering. The conversation assumes a technically literate audience. Terms like CAR-T, ADC, oral SERD, RNAi, exon skipping, rare disease exclusivity, and pivotal data catalysts are part of the working vocabulary. That density is the point. BioCentury This Week is useful when a headline needs context, when a deal needs history, or when a regulatory event needs to be understood as part of a broader operating environment. The style is measured and occasionally dry. The panel can be conversational, but the center of gravity stays on evidence, sector memory, and business consequence. It suits listeners who want biotech news interpreted by people tracking the machinery behind it.
Made for: For biopharma executives, investors, policy watchers, and scientifically fluent listeners who want market context around biotech news. It assumes comfort with sector terms and company-specific discussion.
What sets it apart: The show connects biotech headlines to deal history, regulatory process, financing behavior, and clinical-stage strategy. Its strength is the panel’s habit of stress-testing easy market narratives against specific assets, companies, and policy signals.
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Based on 5 episodes we listened to · September 2026
BioCentury This Week connects biotech deals and market shifts to the pipeline, policy and regional forces shaping company strategy.
BioCentury This Week treats biotech as a business system, tracing how acquisitions, capital markets, regulation and regional competition shape company strategy.
Biotech's bull market gets cross-examined before anyone starts ringing bells.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
Biotech dealmaking keeps moving, but the recovery still depends on policy and regulatory steadiness.
BioCentury This Week presents biotech as steadier than the headlines suggest: markets remain unsettled, yet M&A and financing activity keep moving, and that balance is the point.
European biotech is cast as a contest over speed, capital, and policy.
The piece frames European biotech as a race toward the clinic: faster early human data, faster de-risking, and a clearer path to investment and partnering.
A sharp look at biotech dealmaking and the policy shifts that may change it.
BioCentury This Week keeps its focus on where biotech capital is moving, and it uses a burst of deal news to frame the conversation. It moves through Merck's proposed $6.7 billion bid for Terns and Gilead's proposal to buy Oro with Galapagos, then connects the Gilead thread to a…
A steady case that biotech's rebound may be broader and more durable than the last few attempts.
BioCentury This Week uses its special edition tied to the 2026 Public Markets Preview to test whether biotech's bull market has real staying power.
A Shanghai panel that links China biotech financing, partnering, and global ambition without hand-waving.
BioCentury This Week uses the Shanghai summit to frame a familiar but useful gap: China biotech can be strong at home while still working to widen its global reach.
Biotech conversations past the headline.
Neurotech conversations with the builders themselves.
Biotech strategy from the people building it.
Nature Biotechnology's editors, in conversation with the field.
Steven Hansen says the XBI trailed broader markets in Q3 after M&A, which ran at roughly one $1 billion-plus deal per week from March to July, went quiet after mid-July.
This episode discusses FDA's ambitious proposal to accelerate first-in-human trials, recent billion-dollar biotech deals including Gilead's acquisition, new investment funds, and PDUFA negotiations.
BioCentury This Week's Q2 public markets preview covers how a new Middle East conflict disrupted an otherwise strong biotech start to the year, with nine deals totaling $32 billion in Q1.
This special edition of BioCentury This Week, recorded ahead of BioEquity Europe in Prague, examines why European biotech is losing global competitiveness and what structural changes are needed.
BioCentury This Week covers a week of major biotech deals led by Merck's $6.7 billion Terns acquisition and Gilead's $1.7 billion Uro proposal, then shifts to a report on UK MHRA CEO Lawrence Tallon's clinical trial reform agenda.
This episode discusses Arrowhead's growth in biotech, AI integration in biotech venture capital, Synnovation's deal with Novartis, MFN updates, and the search for a new FDA CBER director.
This episode discusses the current state of biotech capital markets, including follow-on financings and IPOs, analyzes late-stage epilepsy data from Xenon, and explores the pipeline for Friedreich ataxia in a rare disease spotlight.
This episode discusses key takeaways from the East-West Biopharma Summit in Seoul, featuring insights from industry leaders on biopharma trends and networking.
This episode discusses oral selective estrogen receptor degraders in targeted protein degradation, FDA regulatory setbacks for Moderna and Disc Medicine, and a new subscriber lounge at a summit.
Discussion of key biotech catalysts for 2026, including RNAi therapies, new lipid-lowering mechanisms, and China's orphan drug exclusivity regulation.
Biotech's bull is back, but the panel is not calling it a victory lap.
This episode covers recent biotech industry deals, including Biomarin's acquisition of Amicus, and other news from the biopharma sector.
A roundtable discussion on biotech industry trends, including billion-dollar deals, clinical trial data, and FDA developments.
This episode discusses Novo Nordisk's Alzheimer's data for semaglutide and a new vaccine strategy at FDA.
This episode covers Pfizer's acquisition of Metsera, obesity drug data, Jim Wilson's funding model for ultra-rare therapies, and FDA leadership changes.
This episode discusses Pfizer's potential acquisition of Metzera and Novo Nordisk's unsolicited bid for the obesity startup, along with other biotech industry news.
Shanghai sets the frame.
This episode covers major biotech M&A deals, including Novartis's acquisition of muscular dystrophy therapies and Alkermes's buy of Avidel, plus an interview with David Liu on base editing.
This episode covers Genmab's acquisition of Meris, Emma Walmsley's departure from GSK, and regulatory news affecting the biopharma industry.
This episode covers Pfizer's acquisition of obesity startup MetSara, UK drug pricing issues, Trump's deadline for biopharma companies, and narcolepsy data from World Sleep Congress.
This episode covers biotech industry news including David Baltimore's legacy, a new VC fund, GLP-1 assets for MASH, Sanofi's dermatitis data, and Dupixent approval for hives.
This episode discusses Eli Lilly's obesity drug data, the Biosecure Act, Vinay Prasad's return to FDA, and Acadia's revamp in the biotech industry.